About the Company
We do not have any company description for Cabaletta Bio, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Cabaletta Bio, Inc.
230,161 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by ...
Cabaletta Bio Trading Up 7.2 % NASDAQ CABA opened at $1.34 on Friday. The company has a market capitalization of $68.00 million, a PE ratio of -0.62 and a beta of 2.44. Cabaletta Bio, Inc. has a ...
NOTICE: Cabaletta Bio, Inc. Investors with Substantial Losses Have ...
NOTICE: Cabaletta Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CABA March 07, 2022 08:35 PM Eastern Standard Time ...
Cabaletta Bio’s and Gracell’s stock falls sharply as FDA ...
Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug ...
What Kind Of Shareholders Hold The Majority In Cabaletta Bio, Inc.'s ...
October 06, 2021 — 07:20 am EDT Written by Simply Wall St for Simply Wall St -> The big shareholder groups in Cabaletta Bio, Inc. (NASDAQ:CABA) have power over the company.
Cabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You ...
Earnings Estimate Revisions for Cabaletta Bio, Inc. This company is expected to earn -$1.87 per share for the fiscal year ending December 2020, which represents a year-over-year change of 54.1%.
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of ...
Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) have received a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat reports.
Cabaletta Bio, Inc. (CABA) Stock Competitors & Similar Stocks ...
Cabaletta Bio, Inc. (CABA) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.
Cabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This ...
Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases. Cabaletta has 3 potential therapeutics from its ...
Similar Companies
Loading the latest forecasts...